NeuroRx® Changes Name to Neurotherapeutics
Philadelphia, 04 January 2007 - NeuroRx®, the official journal of the American Society for Experimental NeuroTherapeutics (ASENT), published by Elsevier, will be changing its name to Neurotherapeutics as of the January 2007 issue. Elsevier, the Editor-in-Chief and Editorial Board for NeuroRx® and the ASENT Board members worked closely together in 2006 to develop a new name to reinforce the true focus of the journal.
Neurotherapeutics is a unique publication providing critical reviews on selected topics in therapy of neurological disorders. Each quarterly issue focuses on dedicated topic(s), with internationally recognized authorities sharing their in-depth understanding. Neurotherapeutics offers a multidisciplinary perspective on high-profile topics in neurotherapeutics, taking in not just the scientific issues but also their social and ethical ramifications.
“Neurotherapeutics more clearly reflects the intended meaning of the journal title and positions it more accurately in the field,” said Editor-in-Chief, Alan I. Faden, MD.
Citations for prior issues of the journal, which is indexed by PubMed Central and MEDLINE, will be available under both NeuroRx® and Neurotherapeutics.
# # #
The purpose of the American Society for Experimental NeuroTherapeutics is to provide a forum for broadly defined interest areas of academia, government, industry and advocacy concerned with the field of neurotherapeutics; to promote dialogue, understanding and cooperation among the interested groups; to develop information and seek consensus on matters germane to the organization’s mission; and to organize education and training for healthcare practitioners, biomedical scientists and officials participating in the neurotherapeutics field. Visit the Society’s website at www.asent.org.
Elsevier is a world-leading publisher of scientific, technical and medical information products and services. Working in partnership with the global science and health communities, Elsevier’s 7,000 employees in over 70 offices worldwide publish more than 2,000 journals and 1,900 new books per year, in addition to offering a suite of innovative electronic products, such as ScienceDirect, MD Consult, Scopus, bibliographic databases, and online reference works.
Elsevier is a global business headquartered in Amsterdam, The Netherlands and has offices worldwide. Elsevier is part of Reed Elsevier Group plc, a world-leading publisher and information provider. Operating in the science and medical, legal, education and business-to-business sectors, Reed Elsevier provides high-quality and flexible information solutions to users, with increasing emphasis on the Internet as a means of delivery. Reed Elsevier’s ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).
- Contact Information
- Jane Grochowski
- Contact via E-mail
This news content was configured by WebWire editorial staff. Linking is permitted.
News Release Distribution and Press Release Distribution Services Provided by WebWire.